We compared proportions of each myeloid subtype in each patient, finding that SPP1+APOE+ TAM (Diff = 9.5%, p = 0.011) and CD62L+IFN-high neutrophils (Diff = 5.0%, p = 0.046) were significantly enriched in primary tumor patients versus adjacent normal (Fig. 4b). This evidence concerns the gene SELL and neoplasm.